Antibiotic Drug Push By Administration Could Include BARDA Incubator
As NIH workshop discusses novel approaches to combatting antibiotic resistance from monoclonal antibodies to synthetic stool transplants and antimicrobial peptides, plans are underway to expand BARDA’s focus beyond biodefense.
You may also be interested in...
US FDA’s Theresa Mullin envisions having a national catalog of standard core clinical outcomes assessment measures that could apply to every disease area.
Jazz’s REMS patent on distribution of Xyrem does not belong in the Orange Book because it is directed to systems rather than a method of using the drug, court rules, agreeing with FTC’s analysis.
Research institutions, CROs, biopharma industry and other stakeholders are asked to comment on potential governance structure that would determine when trials are needed to address disease outbreaks and other public health emergencies.